Treatment-naive patients with HCV G1/4 infection were randomized to twice-daily danoprevir/r 200/100 mg ( A , n = 92 ) ; 100/100 mg ( B , n = 93 ) ; or 50/100 mg ( C , n = 94 ) plus P/R for 24 weeks ; twice-daily danoprevir/r 100/100 mg ( D , n = 94 ) plus P/R for 12 or 24 weeks ; or P/R alone ( E , n = 44 ) for 48 weeks .